OKYO Pharma

Youtube Subscribe

Open: 1.11 Close: 1.08 Change: -0.03

Our AI found 12 flaws in OKYO Pharma.

This document will help you to evaluate OKYO Pharma without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about OKYO Pharma are: OKYO, Pharma, Ltd, share, outstanding, beta, companys, …

Concept Map

Semantic Network

Stock Summary

OKYO Pharma Limited engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain. Its lead preclinical product candidate is OK-101 for the treatment of dry eye disease. OK-201 is a bov.

Today's Summary

OKYO Pharma Ltd. has 8.41 million shares outstanding. The beta is -2.97, so the companys price volatility has been lower than the market average. The company does not appear to pay any dividends.

Today's News

OKYO Pharma Ltd. has 8.41 million shares outstanding. The beta is -2.97, so the companys price volatility has been lower than the market average. The company does not appear to pay any dividends.

Stock Profile

"OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom."

Keywords

How much time have you spent trying to decide whether investing in OKYO Pharma? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about OKYO Pharma are: OKYO, Pharma, Ltd, share, outstanding, beta, companys, and the most common words in the summary are: state, united, therapeutic, pharmaceutical, pharma, bioscience, biopharma, . One of the sentences in the summary was: has 8.41 million shares outstanding. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #state #united #therapeutic #pharmaceutical #pharma #bioscience #biopharma.

Read more →

Youtube Subscribe

---